The Impact of Immune-Related Adverse Event Severity on Prognosis in Elderly Patients With Nonsmall-Cell Lung Cancer in First-Line Immune Checkpoint Inhibitor Treatment

Overview

Journal Thorac Cancer

Date 2025 Feb 4

PMID 39901355

Authors

Ippei Miyamoto

Tetsuo Shimizu

Mizuki Hanamura

Yu Mizuno

Ryota Nakayama

Ryo Kusahana

Masayuki Nomoto

Yoshiko Nakagawa

Yasuhiro Gon

Affiliations

Soon will be listed here.

Abstract

Background: Recently, the treatment needs of elderly lung cancer patients have become comparable with those of younger patients. This study evaluated the efficacy and safety of first-line immune checkpoint inhibitors (ICI) in elderly patients with nonsmall-cell lung cancer (NSCLC), stratified by immune-related adverse events (irAEs) severity, and identified key prognostic factors.

Methods: This retrospective study targeted patients with advanced or recurrent NSCLC who received ICI therapy as first-line treatment between April 2017 and March 2023.

Result: Of the 138 patients enrolled in this study, 81 and 57 patients were classified into the elderly (aged 70 and above) and nonelderly (under 70 years old) groups, respectively. Severe irAEs were significantly associated with shorter overall survival (OS) in the elderly group (severe irAEs vs. others, 9.9 vs. 24.7 months; p = 0.043) and favorable OS in nonelderly group (severe irAEs vs. others, NR [not reached] vs. 21.0 months, p = 0.026). The OS of patients with severe irAEs was significantly worse in the elderly group than in the nonelderly group (elderly group vs. nonelderly group, 9.9 vs. NR months, p = 0.001). In the multivariate analysis, mild irAEs were associated with a favorable prognosis in elderly patients (hazard ratio, 0.446; p = 0.032).

Conclusion: Severe irAEs demonstrated different outcomes in elderly and nonelderly patients. Contrastingly, mild irAEs were associated with a favorable prognosis in elderly patients, emphasizing the need for appropriate patient selection, early intervention for irAEs and new tools to accurately predict irAE severity in elderly patients.

References

Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E . Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. Oncologist. 2020; 25(4):e679-e683. PMC: 7160399. DOI: 10.1634/theoncologist.2019-0299. View

Abu-Sbeih H, Ali F, Wang X, Mallepally N, Chen E, Altan M . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019; 7(1):93. PMC: 6444537. DOI: 10.1186/s40425-019-0577-1. View

Bellera C, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M . Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012; 23(8):2166-2172. DOI: 10.1093/annonc/mdr587. View

Cook S, Samuel V, Meyers D, Stukalin I, Litt I, Sangha R . Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Netw Open. 2024; 7(1):e2352302. PMC: 10797458. DOI: 10.1001/jamanetworkopen.2023.52302. View

Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F . Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003; 95(5):362-72. DOI: 10.1093/jnci/95.5.362. View

Gullon J, Suarez I, Medina A, Rubinos G, Fernandez R, Gonzalez I . Role of emphysema and airway obstruction in prognosis of lung cancer. Lung Cancer. 2010; 71(2):182-5. DOI: 10.1016/j.lungcan.2010.05.018. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Quoix E, Zalcman G, Oster J, Westeel V, Pichon E, Lavole A . Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011; 378(9796):1079-88. DOI: 10.1016/S0140-6736(11)60780-0. View

10.

Endo S, Honda T, Sato K, Kubota N, Kamoshida T, Mochizuki A . Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study. Cancer Treat Res Commun. 2023; 37:100755. DOI: 10.1016/j.ctarc.2023.100755. View

11.

Khozin S, Abernethy A, Nussbaum N, Zhi J, Curtis M, Tucker M . Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. Oncologist. 2018; 23(3):328-336. PMC: 5905694. DOI: 10.1634/theoncologist.2017-0353. View

12.

Johns A, Yang M, Wei L, Grogan M, Spakowicz D, Patel S . Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. Oncologist. 2023; 28(8):e625-e632. PMC: 10400153. DOI: 10.1093/oncolo/oyad097. View

13.

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S . Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017; 84:212-218. DOI: 10.1016/j.ejca.2017.07.027. View

14.

Yi Y, Ban W, Sohng K . Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. BMC Cancer. 2018; 18(1):1053. PMC: 6206922. DOI: 10.1186/s12885-018-4976-3. View

15.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

16.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

17.

Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T . Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. Eur J Cancer. 2021; 150:63-72. DOI: 10.1016/j.ejca.2021.03.016. View

18.

Gridelli C, Peters S, Velcheti V, Attili I, de Marinis F . Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). ESMO Open. 2023; 8(2):101192. PMC: 10073636. DOI: 10.1016/j.esmoop.2023.101192. View

19.

Saito Z, Fujita K, Okamura M, Ito T, Yamamoto Y, Kanai O . Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older. Cancer Rep (Hoboken). 2021; 4(6):e1405. PMC: 8714532. DOI: 10.1002/cnr2.1405. View

20.

Kurokawa K, Mitsuishi Y, Shimada N, Kawakami Y, Miura K, Miyawaki T . Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. BMC Cancer. 2022; 22(1):1047. PMC: 9535983. DOI: 10.1186/s12885-022-10133-1. View